Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Acquired by American Century Companies Inc.

American Century Companies Inc. raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 46.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 608,457 shares of the biopharmaceutical company's stock after acquiring an additional 193,093 shares during the period. American Century Companies Inc. owned approximately 0.92% of Celldex Therapeutics worth $15,376,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of CLDX. EverSource Wealth Advisors LLC lifted its holdings in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 878 shares during the last quarter. KBC Group NV boosted its holdings in Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares in the last quarter. AlphaQuest LLC grew its stake in shares of Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after acquiring an additional 2,705 shares during the last quarter. E Fund Management Co. Ltd. acquired a new position in shares of Celldex Therapeutics during the fourth quarter valued at about $273,000. Finally, Point72 DIFC Ltd raised its position in shares of Celldex Therapeutics by 101.7% in the 3rd quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company's stock valued at $480,000 after purchasing an additional 7,116 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. The Goldman Sachs Group cut their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. UBS Group started coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $44.00 price target on the stock. Morgan Stanley began coverage on Celldex Therapeutics in a report on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $54.33.

Celldex Therapeutics Stock Down 8.0 %

Shares of NASDAQ CLDX traded down $1.37 during trading on Friday, hitting $15.78. The company had a trading volume of 1,183,579 shares, compared to its average volume of 868,596. Celldex Therapeutics, Inc. has a fifty-two week low of $15.46 and a fifty-two week high of $47.00. The stock has a fifty day simple moving average of $21.18 and a two-hundred day simple moving average of $25.45. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -6.14 and a beta of 1.59.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. On average, analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.